News Articles

Ferring and Evotec Form Strategic Research Alliance in Reproductive Medicine and Women’s Health SAINT-PREX, Switzerland & HAMBURG, Germany -Wednesday 17 October 2018  

(BUSINESS WIRE)-- Ferring Pharmaceuticals and Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced a strategic research alliance to discover and develop new small molecule therapies to treat patients living with fertility and gynaecological...

Ferring and Celmatix Launch Ambitious Genomics Collaboration to Advance Care in Reproductive Medicine and Women’s... -Thursday 30 August 2018  

(BUSINESS WIRE)-- Ferring Pharmaceuticals and Celmatix today announced an ambitious genomics collaboration aimed at uncovering new insights into ovarian biology and accelerating the development of personalized interventions in reproductive medicine and women’s health. This collaboration will...

Ferring’s Heat-Stable Carbetocin Could Save Thousands of Women’s Lives by Preventing Excessive Bleeding... -Monday 23 July 2018  

(BUSINESS WIRE)-- Ferring Pharmaceuticals today announced new data demonstrating that its heat-stable formulation of carbetocin is as effective as the current standard of care, oxytocin, for the prevention of excessive bleeding, also known as postpartum haemorrhage (PPH), after vaginal...

New Analysis of Rekovelle® Data Further Supports Use of AMH to Personalise Fertility Treatment -Tuesday 3 July 2018  

(BUSINESS WIRE) -- Ferring Pharmaceuticals announced today a new analysis* of data from the Phase 3 ESTHER-1 trial1 showing that natural variations in anti-Müllerian hormone (AMH) levels during and between a woman’s menstrual cycle have no clinically relevant impact on ovarian response (the...

Large-Scale Study Provides First-Ever Insights into the Genetic Causes of Bedwetting -Tuesday 29 May 2018  

It is likely to be hereditary: children whose parents wet the bed are more likely to be bedwetters1 The world’s first genome-wide association study (GWAS) in bedwetting identify specific genetic variants that increase the risk of bedwetting Further delineation of the genetic component of...

Ferring Signs Global Agreement to Commercialise Novel Gene Therapy for Bladder Cancer Patients -Thursday 3 May 2018

rAd-IFN/Syn3, a novel gene therapy, is in Phase 3 development to treat high-grade non-muscle invasive bladder cancer patients, who are unresponsive to BCG therapy The US FDA has granted Fast Track and Breakthrough Therapy designations to rAd-IFN/Syn3 Ferring US will create a new oncology...

Ferring Acquires Innovative Biotechnology Company and Microbiome Pioneer Rebiotix Inc. -Thursday 5 April 2018  

Rebiotix’s RBX2660 is a non-antibiotic treatment in Phase 3 development for the prevention of recurrent Clostridium difficile infection (CDI) and has the potential to be the world’s first approved human microbiome product CDI is one of the most common healthcare-associated infections in...

Nocturia: the most common cause of a poor night’s sleep, say experts on World Sleep Day -Friday 16 March 2018  

Nocturia, the need to wake to urinate more than once in the night, is the most common cause of sleep disruption in adults of all ages.1,2 The condition is associated with loss of deep sleep, disruption of daytime functioning and reduced productivity and alertness.3,4,5 In rare cases,...

Ferring Announces Positive Outcome of European Decentralised Procedure (DCP) for Testavan®, a Treatment... -Thursday 15 March 2018

Testavan® expands treatment options for men with hypogonadism, a condition which causes low levels of testosterone and which may adversely affect quality of life and sexual function1-3 Men treated with Testavan achieved normalised testosterone levels after three months, with improvements...

March of Dimes and Ferring Announce New Prematurity Research Center at Imperial College London -Wednesday 7 March 2018  

(BUSINESS WIRE) -- March of Dimes and Ferring Pharmaceuticals today announced that March of Dimes has selected Imperial College London as the first European partner to join its network of Prematurity Research Centers working to find the unknown causes of preterm birth and new ways to prevent...

Ferring Pharmaceuticals and MSD Announce Completion of Largest Clinical Trial Ever Conducted in Postpartum Haemorrhage -Thursday 22 February 2018  

Excessive bleeding after childbirth (postpartum haemorrhage or PPH) is the leading direct cause of maternal mortality worldwide1 The CHAMPION trial is assessing the effectiveness and safety of heat-stable carbetocin vs. oxytocin, the current standard of care, for preventing PPH after...

Ferring Announces 30 Million CHF Investment in New Biotech Centre in Switzerland -Wednesday 14 February 2018

(BUSINESS WIRE) -- Ferring Pharmaceuticals announced today that it is expanding its capabilities in biologics through a new biotech centre which will be installed at the company’s existing headquarters and manufacturing site in Saint-Prex, Switzerland. Over the next three years, Ferring...

Ferring Announces Recipients of Innovation Grants Program 2017-2018 -Friday 26 January 2018

(BUSINESS WIRE)-- Ferring Pharmaceuticals today announced the recipients of the 2017-2018 Innovation Grants Program, an annual initiative of the Ferring Research Institute (FRI) based in San Diego. This global program supports research in the fields of reproductive medicine and women’s health,...

Ferring enters into worldwide OmniAb® platform license agreement with Ligand -Monday 22 January 2018

Ferring Pharmaceuticals will use Ligand’s OmniAb® platform to discover new human monoclonal antibodies Through this platform, Ferring aims to accelerate development solutions for unmet patient needs in reproductive medicine and women’s health, urology and gastroenterology Agreement...

Ferring and the Chinese Academy of Sciences Collaborate to Advance Research in Reproductive Medicine -Thursday 11 January 2018  

(BUSINESS WIRE) -- Ferring Pharmaceuticals and the Chinese Academy of Sciences (CAS) today announced a long-term collaboration to advance basic and translational research in reproductive medicine through the development of novel product candidates and therapeutic strategies. As part of the...

Ferring Receives Swiss Approval For Rekovelle®, The First Personalised Fertility Treatment Using an... -Monday 27 November 2017

(BUSINESS WIRE)-- Ferring Pharmaceuticals announced today that Swissmedic has approved Rekovelle® (follitropin delta) for use in controlled stimulation for induction of the development of multiple follicles in women undergoing assisted reproductive technologies (ART), such as an in...

Ferring Strengthens Growth Hormone Franchise Zomacton® Through Acquisition of ZomaJet™ Needle-Free Injector... -Tuesday 10 October 2017

Ferring enters agreement with Antares Pharma Inc. for worldwide rights to ZomaJet™ needle-free injector device ZomaJet is used to deliver Ferring’s Zomacton® (somatropin), indicated to treat Growth Hormone Deficiency in children and Turner Syndrome in girls ZomaJet helps increase...

Ferring Appoints Klaus Dugi as Executive Vice President and Chief Medical Officer -Tuesday 3 October 2017

(BUSINESS WIRE) -- Ferring Pharmaceuticals announced today that Professor Klaus Dugi has been appointed Executive Vice President and Chief Medical Officer, effective immediately. He will be responsible for Global Medical Affairs, Quality Assurance and Pharmacovigilance. In addition, he will...

Ferring Appoints Lars Peter Brunse to Executive Board -Monday 3 July 2017

(BUSINESS WIRE)-- Ferring Pharmaceuticals announced today that Lars Peter Brunse has been appointed Executive Vice President and Chief Production Officer, and made a member of the Ferring Executive Board, effective immediately. Lars Peter Brunse joined Ferring as Associate Director Technical...

Ferring Appoints Aaron Graff to Executive Board -Thursday 1 June 2017

(BUSINESS WIRE)-- Ferring Pharmaceuticals announced today that Aaron Graff has been appointed Executive Vice President and Chief Commercial Officer and made a member of the Ferring Group Executive Board, effective immediately. Aaron Graff joined Ferring in 2002 as Vice President Global...

Results 1-20 of 34